New ventricular assist device called the PediPump

A new ventricular assist device (VAD) called the PediPump has been developed specifically for use in children. A status report on this new device appears in the July issue of the journal Artificial Organs.

Measuring at just 7mm x 70 mm, this small rotary dynamic VAD is suitable for use in children, including newborns, in treatment of end-stage heart failure. The program that developed the PediPump is a partnership between clinicians at The Children’s Hospital at the Cleveland Clinic and researchers in Biomedical Engineering, The Lerner Research Institute of the Cleveland Clinic.

“Historically, children have had few options for mechanical support of the failing heart,” states lead researcher, Dr. Brian Duncan. “The PediPump is an artificial heart pump designed specifically for children with heart failure. The experimental development of the PediPump and similar devices will give new hope to children with heart failure.”

According to researchers, despite being much smaller than traditional VADs, the PediPump has demonstrated excellent hemodynamic performance and its versatile design will ultimately allow for its use in a variety of clinical settings. Researchers plan to further reduce the size of the PediPump to allow for a totally implantable pediatric VAD.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis